Today we are thrilled to announce our partnership with new portfolio company Acumen Pharmaceuticals, Inc., a clinical-stage drug development company focused on developing a novel therapeutic for #AlzheimersDisease, including ACU193, an investigational humanized monoclonal antibody that selectively targets toxic soluble amyloid-beta oligomers (AβOs). This $50M loan agreement will provide additional operational flexibility and will help fund, among other activities, Acumen’s development program for a subcutaneous form of ACU193.
Our collaboration further demonstrates K2HV’s ability to finance life sciences companies through multiple stages of development, and we look forward to supporting Acumen’s leadership team in realizing their mission of creating a potential best-in-class treatment for Alzheimer’s Disease.
Read more: https://k2hv.com/news